Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > By the way posters

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Dec 07, 2022 4:27pm

198 Views

Post# 35157419

RE:RE:RE:RE:By the way posters

The posters will have to be realeased as an announcmenent by ONC today. The data are now in the public domain (SABC) and represent material information affecting the business.

There can be only one reason for realeasing the data as late as possible. And it's not encouraging.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments